Foghorn Therapeutics Inc.
4.20
-0.17 (-3.89%)
At close: Jan 14, 2025, 3:59 PM
4.24
0.95%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 1.72
Market Cap 233.49M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.85
PE Ratio (ttm) -2.27
Forward PE n/a
Analyst Buy
Ask 6
Volume 68,830
Avg. Volume (20D) 158,032
Open 4.43
Previous Close 4.37
Day's Range 4.13 - 4.46
52-Week Range 2.70 - 10.25
Beta undefined

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 23, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol FHTX

Analyst Forecast

According to 5 analyst ratings, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 209.52% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Foghorn Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $8.14M, reflecting a 41.10% YoY growth and earnings per share of -0.27, making a -52.63% decrease YoY.
1 month ago · Source
+3.96%
Foghorn Therapeutics shares rare trading lower aft... Unlock content with Pro Subscription
4 months ago · Source
+20.93%
Foghorn Therapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $20 price target.